Risk prediction and impaired tactile sensory perception among cancer
patients during chemotherapy 1

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

ABSTRACT

Objectives:

to estimate the prevalence of impaired tactile sensory perception, identify risk factors, and establish a risk prediction model among adult patients receiving antineoplastic chemotherapy.

Method:

historical cohort study based on information obtained from the medical files of 127 patients cared for in the cancer unit of a private hospital in a city in Minas Gerais, Brazil. Data were analyzed using descriptive and bivariate statistics, with survival and multivariate analysis by Cox regression.

Results:

57% of the 127 patients included in the study developed impaired tactile sensory perception. The independent variables that caused significant impact, together with time elapsed from the beginning of treatment up to the onset of the condition, were: bone, hepatic and regional lymph node metastases; alcoholism; palliative chemotherapy; and discomfort in lower limbs.

Conclusion:

impaired tactile sensory perception was common among adult patients during chemotherapy, indicating the need to implement interventions designed for early identification and treatment of this condition.

Related collections

Most cited references 26

Record: found
Abstract: found
Article: not found

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Andy Trotti, A. Colevas, Ann Setser … (2003)

Multiple systems have been developed for grading the adverse effects (AEs) of cancer treatment. The National Cancer Institute Common Toxicity Criteria (CTC) system has substantially evolved since its inception in 1983. The most recent version, CTCAE v3.0 (Common Terminology Criteria for Adverse Events version 3.0) represents the first comprehensive, multimodality grading system for reporting the acute and late effects of cancer treatment. The new CTC requires changes in the application of AE criteria including new guidelines regarding late effects, surgical and pediatric effects, multimodality issues, and for reporting the duration of an effect. It builds on the strengths of previous systems, represents a considerable effort among hundreds of participants, and signifies an international collaboration and consensus of the oncology research community. This article updates recent progress in the evolution of adverse effects grading systems and reviews the development of CTCAE v3.0.

0 comments Cited 219 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.

Andreas Argyriou, Jordi Bruna, Paola Marmiroli … (2012)

The peripheral nervous system can be vulnerable to the toxic action of several drugs since it is not protected as effectively as the central nervous system from noxious exogenous agents. Drug-induced neurotoxicity can affect the nerve fibers or the neuronal bodies (generally the dorsal root ganglia of the primary sensory neurons). Among the neurotoxic drugs antineoplastic agents represent a major clinical problem, given their widespread use and the potential severity of their toxicity. In fact, the peripheral neurotoxicity of antineoplastic agents frequently represents one of their dose-limiting side effects. Moreover, even when antineoplastic agents' peripheral neurotoxicity is not dose-limiting, its onset may severely affect the quality of life of cancer patients and cause chronic discomfort. Among the anticancer chemotherapy drugs, platinum derivates, antitubulins, thalidomide and bortezomib can induce the most severe effects on the peripheral nervous system of the treated patients. Therefore, we will review the features of chemotherapy-induced peripheral neurotoxicity (CIPN) resulting from the administration of these drugs with a focus on new classes of promising antineoplastic agents, such as epothilones and proteasome inhibitors. Copyright Â© 2011 Elsevier Ireland Ltd. All rights reserved.

0 comments Cited 151 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy.

Amteshwar Jaggi, Nirmal Singh (2012)

Anti-cancer drugs such as vincristine, paclitaxel, oxaliplatin, cisplatin and bortezomib are well reported to exert direct and indirect effects on sensory nerves to alter the amplitude of action potential, conduction velocity and induce pain. It results in patient suffering and also limits the treatment with potentially useful anticancer drugs. The different scientists have worked in this area to explore the mechanisms responsible for its pathogenesis. Anti-cancer agents activate plasma membrane localized ion channels on dorsal root ganglia and dorsal horn neurons including sodium, calcium, potassium, glutamate activated NMDA receptors to alter cytosolic ionic mileu particularly intracellular calcium that trigger secondary changes to induce neuropathic pain. These may include opening of mPTP pore on mitochondria to induce intracellular calcium release; activation of protein kinase C; phosphorylation of TRPV; activation of calpases/calpains; generation of nitric oxide and free radicals to induce cytotoxicity to axons and neuronal cell bodies. Furthermore, the inflammatory process initiated in glial cells and macrophages also trigger changes in the sensory neurons to alter nociceptive processing. The present review elaborates the role of all these individual targets in the pathogenesis of anticancer agents-induced neuropathic pain to develop effective therapeutic modalities for pain management. Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

0 comments Cited 93 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (nlm-ta): Rev Lat Am Enfermagem

Journal ID (iso-abbrev): Rev Lat Am Enfermagem

Journal ID (publisher-id): rlae

Title: Revista Latino-Americana de Enfermagem

Publisher: Escola de Enfermagem de Ribeirão Preto / Universidade de São Paulo

ISSN (Print): 0104-1169

ISSN (Electronic): 1518-8345

Publication date (Electronic): 08 January 2018

Publication date Collection: 2017

Volume: 25

Electronic Location Identifier: e2957

Affiliations

[2 ]MSc, Technical Manageress, Hope Oncologia, Coronel Fabriciano, MG, Brazil. Doctoral student, Departamento de Enfermagem Básica, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.

[3 ]PhD, Departamento de Enfermagem Básica, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. Professor, Departamento de Enfermagem, Universidade Estadual de Montes Claros, Montes Claros, MG, Brazil.

[4 ]PhD, Full Professor, Departamento de Enfermagem Básica, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.

Author notes

Corresponding Author: Ana Carolina Lima Ramos Cardoso Hospital Unimed Vale do Aço Rua Ipanema, 86 Centro CEP: 35170-032, Coronel Fabriciano, MG, Brasil E-mail: enf.anacardoso@ 123456gmail.com

Article

Other ID: 00414

DOI: 10.1590/1518-8345.1979.2957

PMC ID: 5768208

PubMed ID: 29319742

SO-VID: c076a428-3d74-45ed-b254-6c7316bba469

License:

This is an open-access article distributed under the terms of the Creative Commons Attribution License

History

Date received : 17 February 2017

Date accepted : 30 August 2017

Page count

Figures: 0, Tables: 6, Equations: 0, References: 22, Pages: 1